Alerts
ESR1 Resistance Is Becoming a Treatment Pathway, Not a Footnote
Peer-reviewed Phase III evERA results show giredestrant plus everolimus substantially extended progression-free survival after CDK4/6 inhibitor treatment in ER-positive, HER2-negative advanced breast cancer, with the strongest effect in ESR1-mutated disease.
Mpox Is Settling In
Medical Debt Is Becoming a Cancer Stage
Narcolepsy Gets Treated at the Cause
Lymphoma Is Testing How Far Chemo-Free Care Can Go
Myositis Finally Gets a Targeted Signal
Five Outbreaks Closed. Polio Isn’t.
Cancer Survivorship Standards Are Still Mostly Paper
Europe Has The Mosquitoes. Not The Tools.
Breast Cancer Immunotherapy Has a New Problem: Who Gets the Second Checkpoint?
Free IPM Alliance Newsletter
Insights on science, policy and access in personalised medicine.